Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk (Q36576583)

15 August 2017

1 reference

title

Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk (English)

1 reference

15 August 2017

1 reference

Steven R Smith

1

1 reference

15 August 2017

1 June 2006

1 reference

15 August 2017

1 reference

15 August 2017

14 Suppl 3

1 reference

15 August 2017

128S-134S

1 reference

Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men.

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Insulin resistance syndrome, body mass index and the risk of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Resistin and obesity-associated insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Adiponectin as a biomarker of the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Adiponectin and Metabolic Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Cardiovascular morbidity and mortality associated with the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2006.292

31 March 2020

Identifiers

DOI

10.1038/OBY.2006.292

1 reference

release_rqa42xtotzhs3k5wyo5r6wix5e

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rqa42xtotzhs3k5wyo5r6wix5e

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16931494

1 reference

PubMed ID

16931494